Zacks Research Estimates McKesson’s Q3 Earnings (NYSE:MCK)

McKesson Corporation (NYSE:MCK) – Equities research analysts at Zacks Research raised their Q3 2026 earnings per share (EPS) estimates for McKesson in a research report issued to clients and investors on Wednesday, August 27th. Zacks Research analyst Team now forecasts that the company will earn $9.68 per share for the quarter, up from their prior estimate of $9.56. The consensus estimate for McKesson’s current full-year earnings is $32.77 per share. Zacks Research also issued estimates for McKesson’s Q4 2026 earnings at $10.61 EPS, FY2026 earnings at $37.12 EPS and FY2028 earnings at $46.77 EPS.

A number of other analysts have also weighed in on MCK. Wall Street Zen lowered shares of McKesson from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 13th. Evercore ISI increased their price objective on McKesson from $760.00 to $800.00 and gave the stock an “outperform” rating in a report on Wednesday, July 9th. Morgan Stanley reissued an “overweight” rating and set a $810.00 target price (up from $770.00) on shares of McKesson in a research note on Wednesday, July 16th. Cowen restated a “buy” rating on shares of McKesson in a report on Thursday, August 7th. Finally, Bank of America lifted their price target on shares of McKesson from $755.00 to $800.00 and gave the company a “buy” rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $725.10.

McKesson Stock Up 0.8%

Shares of McKesson stock opened at $686.44 on Monday. The company’s fifty day simple moving average is $702.44 and its two-hundred day simple moving average is $688.57. McKesson has a 12-month low of $464.42 and a 12-month high of $737.89. The firm has a market cap of $85.38 billion, a PE ratio of 27.37, a price-to-earnings-growth ratio of 1.37 and a beta of 0.51.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, August 6th. The company reported $8.26 EPS for the quarter, missing the consensus estimate of $8.33 by ($0.07). The firm had revenue of $97.83 billion during the quarter, compared to analysts’ expectations of $95.93 billion. McKesson had a negative return on equity of 196.66% and a net margin of 0.84%.The firm’s quarterly revenue was up 23.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $7.88 earnings per share.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Tuesday, September 2nd will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 2nd. This is a positive change from McKesson’s previous quarterly dividend of $0.71. This represents a $3.28 annualized dividend and a yield of 0.5%. McKesson’s payout ratio is currently 13.08%.

Insiders Place Their Bets

In related news, CEO Brian S. Tyler sold 19,371 shares of McKesson stock in a transaction dated Friday, July 11th. The shares were sold at an average price of $708.09, for a total transaction of $13,716,411.39. Following the completion of the transaction, the chief executive officer directly owned 27,872 shares of the company’s stock, valued at $19,735,884.48. This trade represents a 41.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $663.67, for a total transaction of $218,347.43. Following the sale, the chief accounting officer directly owned 657 shares in the company, valued at $436,031.19. The trade was a 33.37% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,930 shares of company stock valued at $44,112,466. 0.08% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On McKesson

Several large investors have recently made changes to their positions in MCK. GAMMA Investing LLC increased its position in McKesson by 75,632.7% during the 1st quarter. GAMMA Investing LLC now owns 2,393,152 shares of the company’s stock valued at $1,610,567,000 after buying an additional 2,389,992 shares in the last quarter. Norges Bank bought a new position in shares of McKesson during the second quarter valued at $1,346,661,000. Alliancebernstein L.P. increased its holdings in shares of McKesson by 150.4% during the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after acquiring an additional 1,362,386 shares in the last quarter. Nuveen LLC purchased a new position in shares of McKesson in the 1st quarter worth about $475,235,000. Finally, Farallon Capital Management LLC bought a new position in McKesson in the 4th quarter worth about $348,044,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.